European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment. (October 2020)

• Record Type: Journal Article
• Authors: Derksen, Jeroen W.G.; Warren, Graham W.; Jordan, Karin; Rauh, Stefan; Vera García, Ruth; O'Mahony, Deirdre; Ahmed, Samreen; Vuylsteke, Peter; Radulovic, Sinisa; Tsoukalas, Nikolaos; Wysocki, Piotr J.; Borner, Markus; Cesas, Alvydas; Elme, Anneli; Minn, Heikki; Ullenhag, Gustav J.; Roodhart, Jeanine M.L.; Koopman, Miriam; May, Anne M.
• Is Part Of: European journal of cancer. Volume 138(2020)
• Page Start: 99
• Page End: 108
• Publication Date: 2020-10
• Subjects: Smoking -- Cessation -- Supportive care -- Cancer -- Oncology; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2020.07.020
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Smoking cessation after a cancer diagnosis is associated with improved overall survival. Few studies have reported oncologists' cessation practice patterns, but differences between the curative and palliative settings have not been described. We aimed to study the oncologist's perceptions on patients' tobacco use, current practices and barriers to providing smoking cessation support, while distinguishing between treatment with curative (C) and palliative (P) intent. Methods: In 2019, an online 34-item survey was sent to approximately 6235 oncologists from 16 European countries. Responses were descriptively reported and compared by treatment setting. Results: Responses from 544 oncologists were included. Oncologists appeared to favour addressing tobacco in the curative setting more than in the palliative setting. Oncologists believe that continued smoking impacts treatment outcomes (C: 94%, P: 74%) and that cessation support should be standard cancer care (C: 95%, P: 63%). Most routinely assess tobacco use (C: 93%, P: 78%) and advise patients to stop using tobacco (C: 88%, P: 54%), but only 24% (P)–39% (C) routinely discuss medication options, and only 18% (P)–31% (C) provide cessation support. Hesitation to remove a pleasurable habit (C: 13%, P: 43%) and disbelieve on smoking affecting outcomes (C: 3%, P: 14%) were disparate barriers between the curative and palliative settings ( p < 0.001), but dominant barriers of time, resources, education and patient resistance were similar between settings. Conclusion: Oncologists appear to favour addressing tobacco use more in the curative setting; however, they discuss medication options and/or provide cessation support in a minority of cases. All patients who report current smoking should have access to evidence-based smoking cessation support, also patients treated with palliative intent given their increasing survival. Highlights: Most oncologists ask about tobacco use and advise patients to quit, but few provide assistance to help patients quit smoking. Oncologists address tobacco use more frequently in the curative setting than in the palliative setting. Inability, resistance, lack of time, education and resources were barriers comparable in curative and palliative setting. Smoking cessation programs should be available to all patients who report smoking. Given the increasing survival of stage IV patients, smoking cessation should be focused on in the palliative setting.